- Home
- MBAV vs PGEN Comparison
MBAV vs PGEN Comparison
Compare MBAV & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBAV
- PGEN
- Stock Information
- Founded
- MBAV 2024
- PGEN 1998
- Country
- MBAV United States
- PGEN United States
- Employees
- MBAV N/A
- PGEN N/A
- Industry
- MBAV
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- MBAV
- PGEN Health Care
- Exchange
- MBAV NYSE
- PGEN Nasdaq
- Market Cap
- MBAV 360.4M
- PGEN 292.6M
- IPO Year
- MBAV 2024
- PGEN N/A
- Fundamental
- Price
- MBAV $10.03
- PGEN $0.90
- Analyst Decision
- MBAV
- PGEN Buy
- Analyst Count
- MBAV 0
- PGEN 5
- Target Price
- MBAV N/A
- PGEN $7.00
- AVG Volume (30 Days)
- MBAV 20.8K
- PGEN 858.0K
- Earning Date
- MBAV 01-01-0001
- PGEN 11-14-2024
- Dividend Yield
- MBAV N/A
- PGEN N/A
- EPS Growth
- MBAV N/A
- PGEN N/A
- EPS
- MBAV N/A
- PGEN N/A
- Revenue
- MBAV N/A
- PGEN $3,963,000.00
- Revenue This Year
- MBAV N/A
- PGEN N/A
- Revenue Next Year
- MBAV N/A
- PGEN $211.35
- P/E Ratio
- MBAV N/A
- PGEN N/A
- Revenue Growth
- MBAV N/A
- PGEN N/A
- 52 Week Low
- MBAV $9.97
- PGEN $0.77
- 52 Week High
- MBAV $10.15
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- MBAV N/A
- PGEN 52.02
- Support Level
- MBAV N/A
- PGEN $0.77
- Resistance Level
- MBAV N/A
- PGEN $1.05
- Average True Range (ATR)
- MBAV 0.00
- PGEN 0.07
- MACD
- MBAV 0.00
- PGEN -0.00
- Stochastic Oscillator
- MBAV 0.00
- PGEN 47.46
About MBAV M3-BRIGADE ACQUISITION V CORP
M3-Brigade Acquisition V Corp is a blank check company.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.